Featured Research

from universities, journals, and other organizations

Potential New Treatment For Insulin-dependent Diabetes

Date:
September 28, 2005
Source:
Journal of Experimental Medicine
Summary:
Scientists in Japan have found a way to improve on a promising diabetes treatment. In the October 3 issue of The Journal of Experimental Medicine, Masaru Taniguchi and colleagues report that transplanted insulin-producing cells survive better when the activation of a specific type of immune cell is blocked.

Scientists in Japan have found a way to improve on a promising diabetestreatment. In the October 3 issue of The Journal of ExperimentalMedicine, Masaru Taniguchi and colleagues report that transplantedinsulin-producing cells survive better when the activation of aspecific type of immune cell is blocked.

Insulin-dependent diabetes is caused by the destruction of theinsulin-producing cells in the pancreas (called islet cells) byauto-reactive T cells. The loss of insulin results in an inability tocontrol blood sugar levels. Transplantation of islet cells is aneffective way to restore insulin production, but this therapy requireslife-long immunosuppression of the patient. Even withimmunosuppression, up to half of the transplanted cells are rapidlydestroyed by the patient's own T cells.

Taniguchi's group used a mouse model to show that a subset of cellsknown as natural killer T (NKT) cells instigates the rapid destructionof the islet cells. NKT cells become activated -- likely in response tothe stress of the transplant procedure -- and produce an inflammatorymolecule called interferon (IFN)-gamma, which helps to activate theauto-reactive T cells. In mice that lack NKT cells or are unable toproduce IFN-gamma, the transplanted cells survived.

The group went on to show that multiple doses of a drug (calledalpha-galactosylceramide), which activates NKT cells in single doses,caused these cells to produce less IFN-gamma. The decreased IFN-gammaproduction protected the transplanted islet cells. The authors thussuggest that multiple doses of the same compound, currently in clinicaltrials in humans, might help prevent the early loss of transplantedislet cells in patients with insulin-dependent diabetes.


Story Source:

The above story is based on materials provided by Journal of Experimental Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Experimental Medicine. "Potential New Treatment For Insulin-dependent Diabetes." ScienceDaily. ScienceDaily, 28 September 2005. <www.sciencedaily.com/releases/2005/09/050928233735.htm>.
Journal of Experimental Medicine. (2005, September 28). Potential New Treatment For Insulin-dependent Diabetes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/09/050928233735.htm
Journal of Experimental Medicine. "Potential New Treatment For Insulin-dependent Diabetes." ScienceDaily. www.sciencedaily.com/releases/2005/09/050928233735.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins